MedPath

Amitiza

These highlights do not include all the information needed to use AMITIZA safely and effectively. See full prescribing information for AMITIZA. AMITIZA (lubiprostone) capsule, gelatin coated for oral use Initial U.S. Approval: 2006

Approved
Approval ID

417aa15d-ac74-4fa8-a312-6e51e82ba70c

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Apr 25, 2019

Manufacturers
FDA

Lake Erie Medical DBA Quality Care Products LLC

DUNS: 831276758

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

lubiprostone

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code35356-500
Application NumberNDA021908
Product Classification
M
Marketing Category
C73594
G
Generic Name
lubiprostone
Product Specifications
Route of AdministrationORAL
Effective DateDecember 19, 2018
FDA Product Classification

INGREDIENTS (7)

lubiprostoneActive
Quantity: 24 ug in 1 1
Code: 7662KG2R6K
Classification: ACTIB
sorbitolInactive
Code: 506T60A25R
Classification: IACT
medium-chain triglyceridesInactive
Code: C9H2L21V7U
Classification: IACT
FD&C red no. 40Inactive
Code: WZB9127XOA
Classification: IACT
waterInactive
Code: 059QF0KO0R
Classification: IACT
gelatinInactive
Code: 2G86QN327L
Classification: IACT
D&C yellow no. 10Inactive
Code: 35SW5USQ3G
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.